MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and also Increasing Healthy And Balanced Life Expectancy

MyMD Pharmaceuticals, Inc. MYMD Stock (” MyMD” or “the Business”), a medical phase pharmaceutical business dedicated to prolonging healthy life expectancy, today announced that the very first person has been signed up in the Firm’s Stage 2 medical trial of lead candidate MYMD-1, an oral immune regulator drug, as a treatment for postponing aging and also expanding healthy and balanced life expectancy.

The primary endpoint for the Phase 2 double-blind, placebo-controlled professional trial is to achieve a reduction in the circulating levels of (TNF-α), growth death element receptor I (TNFRI) and IL-6. TNF-α and also IL-6 are the healthy proteins in the body that create inflammation and aid trigger the process of aging. The additional measures of the trial will be the safety and security, tolerability, and pharmacokinetics in this population of clients.

” In a Stage 1 clinical test of MYMD-1, we showed the medication’s statistically significant efficiency in decreasing degrees of TNF-α, a principal in causing pathological aging, in the blood. The FDA has authorized TNF-α reduction as the primary endpoint for our Phase 2 study, which our team believe settings us well for a successful Phase 2 end result,” stated Chris Chapman, M.D., Head Of State, Director as well as Chief Medical Officer of MyMD. “The initiation of client enrollment in this research study advancements our goal to reduce the aging process, prevent loss of muscle mass tissue in aging, limitation frailty, and extend healthy lifespan.”

MyMD has mentioned that there are no FDA-approved medications for treating aging problems and also extending healthy life-span human beings, a market anticipated to be at least $600 billion by 20251 according to a significant financial investment bank. TNF-α blockers are the most recommended drugs by income, a worldwide market of approximately $40 billion annually,2 and also, according to Nature Aging journal,3 a stagnation in maturing that would certainly enhance life span by one year deserves $38 trillion and by 10 years is worth $367 trillion.

In addition to aging, MYMD-1’s distinctive action in controling the immune system as well as treating chronic swelling is being created for the treatment of autoimmune disease, including rheumatoid arthritis (RA), numerous sclerosis (MS), diabetic issues, as well as inflammatory bowel illness.

” We mean to begin creating protocols for a Phase 2 pilot research of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman noted. “The climbing prevalence of rheumatoid arthritis and various other autoimmune as well as inflammatory conditions are driving need for TNF preventions like MYMD-1, and also our team believe our by mouth administered medicine with really reduced toxicity would be turbulent to the $60 billion market for RA if authorized by the FDA for this indicator.”

Rheumatoid joint inflammation impacts about 40 million people around the world.4.

Regarding MYMD-1.

Initially developed for autoimmune illness, MYMD-1’s main purpose is to reduce the aging procedure, stop sarcopenia and frailty, and also expand healthy lifespan. Due to the fact that it can go across the blood-brain barrier as well as get to the central nerve system (CNS), MYMD-1 is additionally positioned to be a possible therapy for brain-related conditions. Its mechanism of activity and also efficacy in conditions including several sclerosis (MS) and also thyroiditis have been examined with collaborations with a number of academic institutions. MYMD-1 is also revealing promise in pre-clinical studies as a prospective treatment for article- COVID-19 problems and also as an anti-fibrotic as well as anti-proliferation restorative.

MYMD-1 has actually shown effectiveness in pre-clinical researches in controling the body immune system by carrying out as a discerning inhibitor of tumor necrosis factor-alpha (TNF-α), a chauffeur of persistent inflammation. Unlike other treatments, MYMD-1 has actually been shown in these pre-clinical researches to selectively block TNF-α when it ends up being overactivated in autoimmune conditions and cytokine tornados, however not block it from doing its normal work of being a first responder to any regular sort of modest infection. MYMD-1’s ease of dental dosing is an additional differentiator contrasted to currently offered TNF-α blockers, every one of which call for shipment by injection or mixture. No authorized TNF inhibitor has actually ever before been dosed orally. Additionally, the drug is not immunosuppressive and has not been shown to trigger the severe side effects common with standard therapies that treat swelling.

Regarding MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical business committed to extending healthy life expectancy, is focused on developing two unique healing systems that deal with the reasons for disease instead of only attending to the signs and symptoms. MYMD-1 is a medication system based upon a scientific phase tiny particle that manages the body immune system to manage TNF-α, which drives persistent inflammation, and also various other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to postpone aging, increase longevity, as well as treat autoimmune diseases and COVID-19- connected depression. The Company’s 2nd medicine platform, Supera-CBD, is being established to treat chronic discomfort, addiction and also epilepsy. Supera-CBD is an unique synthetic derivative of cannabidiol (CBD) as well as is being created to attend to and improve upon the swiftly expanding CBD market, that includes both FDA authorized drugs as well as CBD products not presently controlled as medications. For more details, visit

You may also like